Volitionrx Limited (VNRX) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures edge up with earnings in focus; PayPal jumps
- Oil prices rise 1% as hostilities worsen in the Middle East
- Dollar on back foot as softer US inflation dims Fed hike bets
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
May 19, 2020 4:01 PM EDTAUSTIN, Texas, May 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of... More
